Skip to main content

Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma

CBE ID
3661
1.4 Project
Primary Care and Chronic Illness
Endorsed
Endorsement Status
Endorsed
1.1 New or Maintenance
Maintenance
E&M Cycle
Fall 2021
Is Under Review
No
Next Planned Maintenance Review
Primary Care and Chronic Illness Fall 2025
1.3 Measure Description

Percentage of surgical pathology reports for primary colorectal, endometrial, gastroesophageal or small bowel carcinoma, biopsy or resection, that contain impression or conclusion of or recommendation for testing of mismatch repair (MMR) by immunohistochemistry (biomarkers MLH1, MSH2, MSH6, and PMS2), or microsatellite instability (MSI) by DNA-based testing status, or both

    • 1.14 Numerator

      Surgical pathology reports that contain impression or conclusion of or recommendation for testing of MMR by immunohistochemistry, MSI by DNA-based testing status, or both

    • 1.15 Denominator

      All surgical pathology reports for primary colorectal, endometrial, gastroesophageal or small bowel carcinoma, biopsy or resection

    • Exclusions

      1) Patients with an existing diagnosis of Lynch Syndrome 

       

      2) Squamous cell carcinoma of the esophagus

    • Most Recent Endorsement Activity
      Endorsed Primary Care and Chronic Illness Fall Cycle 2021
      Initial Endorsement
      Last Updated
    • Steward
      College of American Pathologists
      Steward Organization Email
      [email protected]
      Steward Organization Copyright

      © College of American Pathologists. All rights reserved. The College of American Pathologists (CAP) owns all rights, title, and interests in this quality measure. This quality measure is provided solely for the benefit of CAP, its members and the Pathologists Quality Registry for the purposes specified herein and for other CAP purposes. It may not be used by other parties except with prior written approval of the CAP. Email [email protected] for more information.